VivoSeq
Other

BRAF

3

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

BRAF is an early-stage landscape with 3 programs across 1 company. The most active players are Roche.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Atezolizumab

Roche

Bevacizumab

Bio-Thera Solutions

Cobimetinib

Roche

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Recruiting1 · 20%
Unknown status1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Recruiting·—·Phase 2·NCT04943224·12 enrolled
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT02296203·27 enrolled
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Completed·UUniversitair Ziekenhuis Brussel·Phase 2·NCT02296996·25 enrolled
Cobimetinib for BRAF-wild-type or Mutated Histiocytoses
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04007848·54 enrolled
Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03175432·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)